直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

Prosecution First Blog

Third-party submissions may provide efficient means to get art before the PTO

March 07, 2013

Authored and Edited by Michele C. Bosch

As of September 16, 2012, third parties have been able to submit “patents, published patent applications, or other printed publications of potential relevance to examination” in pending patent applications. 37 C.F.R. § 1.290(a). And although it is not yet clear how much of an effect such submissions will have on the quality of granted patents, these so-called “Preissuance Submissions” provide a number of advantages over other procedures available to third parties during examination or in post-grant scenarios.

Among the advantages of these submissions are cost and anonymity. The filing fee is less than two-hundred dollars for submission of ten documents and corresponding comments, and the real party in interest need not be identified. Such submissions cannot, however, be made by a party that has a duty of disclosure in the application.

Perhaps most attractive to potential third-party submitters is the lack of estoppel associated with preissuance submissions. Specifically, despite the fact that the submitter can make comments as to the relevance of cited documents, the significant estoppel that may result from post-grant or inter partes review does not apply to preissuance submissions. Any comments provided with third-party submissions, however, must be limited—that is to say, the submitter cannot appear to participate in prosecution and is not permitted to make subsequent comments on the art once it is submitted. As such, by making such submissions, one runs the risk that what may be the “best” art will be overcome.

There are also strict time limits for making these submissions, i.e., before the earlier of a notice of allowance or the later of six months from publication or first action rejecting the claims. With this in mind, would-be submitters are wise to consider monitoring continuing applications by competitors or those thought to be targeting their products during prosecution, and possibly submitting documents early to avoid missing the opportunity due to a quick allowance. It should be noted though that in such scenarios one may not be able to provide the most effective statement of relevance because the claims being sought would not yet be published.

Lastly, it is worth noting that preissuance submissions are not limited to documents that are prior art to the application. Accordingly, one can conceive of scenarios in which documents that are not prior art are submitted to raise issues that might not otherwise be raised in reexamination or inter partes review, e.g., documents that raise questions as to enablement or the meaning of a term.

Tags

Third-Party Submissions

Contacts

Michele C. Bosch
Partner
Washington, DC
+1 202 408 4193
Email

Copyright © 2013 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 

DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. Additional disclaimer information. 

Related Insights

Webinar

Data and Market Exclusivity: An Update on China’s New Law and Comparisons to the US and Europe

November 19, 2026

Webinar

Conference

IAM Live: Navigating the UPC 2026

November 4, 2026

Paris

Conference

2026 TIPA International Symposium

October 30, 2026

Taipei City

Conference

2nd Annual Forum on Pharma & Biotech Patent Litigation USA & Canada

October 14-16, 2026

New York

Webinar

2026 Inventive Step in Europe and the US: Comparing the UPC, EPO and National Approaches

October 14, 2026

Webinar

Articles

Who Is a “Consumer?” The Supreme Court Takes Up the Video Privacy Protection Act

October 12, 2026

INCONTESTABLE® Blog

Federal Court Orders Rebel Creamery to Redesign Packaging and Disgorge $23.8 Million in Van Leeuwen Trade Dress Case

October 7, 2026

Articles

California Court Considers CIPA’s Application to Online Tracking as New Law Limits Private Actions

October 7, 2026

Articles

U.S. and European Automotive Updates: Installment 2

October 2026

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP